Barclays analyst Carter Gould raised the firm’s price target on Eli Lilly to $680 from $630 and keeps an Overweight rating on the shares. The analyst remains positively biased on U.S. biopharmaceuticals into most Q4 setups, “leaning into recent winners.” The firm recommends weighting towards names with strong prescription trends, supportive guides and potential upside to 2024 numbers. It prefers Eli Lilly (LLY), Merck (MRK), AbbVie (ABBV) Regeneron (REGN). Barclays says Bristol-Myers (BMY) and Pfizer (PFE) are the “most challenged.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- New production lapses found at Eli Lilly plant, Reuters reports
- Novo Nordisk, Eli Lilly, others raise prices of hundreds of drugs, WSJ reports
- Bank of America Pounds the Table on Eli Lilly Stock
- Eli Lilly price target raised to $763 from $727 at Morgan Stanley
- Regeneron to test Wegovy drug combos to protect muscle mass, Bloomberg says
